IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Iovance reported Q2 2026 revenue of approximately $99M (66% YoY growth), exceeding guidance by 10%. The company maintains ~$304M cash with runway into H2 2028, operates 95 authorized treatment centers in North America, and achieved 56% gross margin (excluding D&A) in Q2 2026 and 50% YTD. The pipeline includes registrational trials for lifileucel in frontline melanoma (TILVANCE-301, n=670), post-anti-PD-1 NSCLC (IOV-LUN-202, 25.6% ORR), advanced sarcomas (SARATOGA, 50% ORR), endometrial cancer (IOV-END-201), plus next-generation programs (IOV-4001, IOV-3001, IOV-5001). No material financing, M&A, or corporate events disclosed; this is primarily an operational and clinical progress update.
Why this rating
Strong revenue growth (66% YoY) and margin expansion are meaningful operational wins for a ~$535M market-cap biotech. Cash runway to H2 2028 and pipeline progress reduce near-term risk but are not transformational at current scale. Multiple registrational trials provide future upside but remain uncertain.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.